99 related articles for article (PubMed ID: 12373740)
1. Adenosine A2A antagonism reverses levodopa-induced motor alterations in hemiparkinsonian rats.
Bové J; Marin C; Bonastre M; Tolosa E
Synapse; 2002 Dec; 46(4):251-7. PubMed ID: 12373740
[TBL] [Abstract][Full Text] [Related]
2. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Marin C; Jiménez A; Bonastre M; Vila M; Agid Y; Hirsch EC; Tolosa E
Synapse; 2001 Oct; 42(1):40-7. PubMed ID: 11668589
[TBL] [Abstract][Full Text] [Related]
3. Inhibitory effect of 8-(3-chlorostryryl) caffeine on levodopa-induced motor fluctuation is associated with intracellular signaling pathway in 6-OHDA-lesioned rats.
Song L; Kong M; Ma Y; Ba M; Liu Z
Brain Res; 2009 Jun; 1276():171-9. PubMed ID: 19393228
[TBL] [Abstract][Full Text] [Related]
4. Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Bové J; Serrats J; Mengod G; Cortés R; Aguilar E; Marin C
Synapse; 2006 Jun; 59(7):435-44. PubMed ID: 16498608
[TBL] [Abstract][Full Text] [Related]
5. CSC counteracts l-DOPA-induced overactivity of the corticostriatal synaptic ultrastructure and function in 6-OHDA-lesioned rats.
Huang YX; Luo WF; Li D; Hu WD; Liu CF
Brain Res; 2011 Feb; 1376():113-21. PubMed ID: 21195062
[TBL] [Abstract][Full Text] [Related]
6. Bilateral subthalamic nucleus lesion reverses L-dopa-induced motor fluctuations and facilitates dyskinetic movements in hemiparkinsonian rats.
Marin C; Jiménez A; Tolosa E; Bonastre M; Bové J
Synapse; 2004 Feb; 51(2):140-50. PubMed ID: 14618681
[TBL] [Abstract][Full Text] [Related]
7. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
Pinna A; Fenu S; Morelli M
Synapse; 2001 Mar; 39(3):233-8. PubMed ID: 11284438
[TBL] [Abstract][Full Text] [Related]
8. Effect of acute and chronic administration of U50,488, a kappa opioid receptor agonist, in 6-OHDA-lesioned rats chronically treated with levodopa.
Marin C; Bové J; Bonastre M; Tolosa E
Exp Neurol; 2003 Sep; 183(1):66-73. PubMed ID: 12957489
[TBL] [Abstract][Full Text] [Related]
9. CSC, an adenosine A(2A) receptor antagonist and MAO B inhibitor, reverses behavior, monoamine neurotransmission, and amino acid alterations in the 6-OHDA-lesioned rats.
Aguiar LM; Macêdo DS; Vasconcelos SM; Oliveira AA; de Sousa FC; Viana GS
Brain Res; 2008 Jan; 1191():192-9. PubMed ID: 18164694
[TBL] [Abstract][Full Text] [Related]
10. Improvement of postural adjustment steps in hemiparkinsonian rats chronically treated with caffeine is mediated by concurrent blockade of A1 and A2A adenosine receptors.
Bata-García JL; Tun-Cobá L; Alvarez-Cervera FJ; Villanueva-Toledo JR; Heredia-López FJ; Góngora-Alfaro JL
Neuroscience; 2010 Mar; 166(2):590-603. PubMed ID: 20056138
[TBL] [Abstract][Full Text] [Related]
11. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
Pérez V; Sosti V; Rubio A; Barbanoj M; Rodríguez-Alvarez J; Kulisevsky J
Eur J Pharmacol; 2007 Dec; 576(1-3):83-90. PubMed ID: 17888901
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of adenosine antagonists in two models of parkinsonian tremor.
Trevitt J; Kawa K; Jalali A; Larsen C
Pharmacol Biochem Behav; 2009 Nov; 94(1):24-9. PubMed ID: 19602422
[TBL] [Abstract][Full Text] [Related]
13. Caffeine and CSC, adenosine A2A antagonists, offer neuroprotection against 6-OHDA-induced neurotoxicity in rat mesencephalic cells.
Nobre HV; Cunha GM; de Vasconcelos LM; Magalhães HI; Oliveira Neto RN; Maia FD; de Moraes MO; Leal LK; Viana GS
Neurochem Int; 2010 Jan; 56(1):51-8. PubMed ID: 19782116
[TBL] [Abstract][Full Text] [Related]
14. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Marin C; Aguilar E; Bonastre M; Tolosa E; Obeso JA
Exp Neurol; 2005 Mar; 192(1):184-93. PubMed ID: 15698633
[TBL] [Abstract][Full Text] [Related]
15. NR2B selective NMDA receptor antagonist CP-101,606 prevents levodopa-induced motor response alterations in hemi-parkinsonian rats.
Wessell RH; Ahmed SM; Menniti FS; Dunbar GL; Chase TN; Oh JD
Neuropharmacology; 2004 Aug; 47(2):184-94. PubMed ID: 15223297
[TBL] [Abstract][Full Text] [Related]
16. Involvement of adenosinergic receptor system in an animal model of tardive dyskinesia and associated behavioural, biochemical and neurochemical changes.
Bishnoi M; Chopra K; Kulkarni SK
Eur J Pharmacol; 2006 Dec; 552(1-3):55-66. PubMed ID: 17064683
[TBL] [Abstract][Full Text] [Related]
17. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2007 Jan; 25(1):259-69. PubMed ID: 17241287
[TBL] [Abstract][Full Text] [Related]
18. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
Rose S; Ramsay Croft N; Jenner P
Brain Res; 2007 Feb; 1133(1):110-4. PubMed ID: 17196564
[TBL] [Abstract][Full Text] [Related]
19. Adenosine receptor-mediated modulation of dopamine release in the nucleus accumbens depends on glutamate neurotransmission and N-methyl-D-aspartate receptor stimulation.
Quarta D; Borycz J; Solinas M; Patkar K; Hockemeyer J; Ciruela F; Lluis C; Franco R; Woods AS; Goldberg SR; Ferré S
J Neurochem; 2004 Nov; 91(4):873-80. PubMed ID: 15525341
[TBL] [Abstract][Full Text] [Related]
20. SCH 58261, an A(2A) adenosine receptor antagonist, counteracts parkinsonian-like muscle rigidity in rats.
Wardas J; Konieczny J; Lorenc-Koci E
Synapse; 2001 Aug; 41(2):160-71. PubMed ID: 11400182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
